Compared to Estimates, Ultragenyx (RARE) Q3 Earnings: A Look at Key MetricsZacks Investment Research • 11/06/24
RARE's Wilson Disease Candidate Betters Standard Therapy in StudyZacks Investment Research • 10/04/24
Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson DiseaseGlobeNewsWire • 10/03/24
Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual MeetingGlobeNewsWire • 09/26/24
Amlogenyx Inc. Closes Successful Seed Funding Led by GordonMD® Global Investments LPBusiness Wire • 08/02/24
Compared to Estimates, Ultragenyx (RARE) Q2 Earnings: A Look at Key MetricsZacks Investment Research • 08/02/24
Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate UpdateGlobeNewsWire • 08/01/24
Ultragenyx (RARE) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 ReleaseZacks Investment Research • 07/25/24
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: AnalystBenzinga • 07/22/24
Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewsWire • 06/14/24
Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewsWire • 06/12/24
Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)GlobeNewsWire • 06/12/24